Avance Clinical has a dedicated scientific and regulatory affairs service, ClinicReady, headed up by Gabriel Kremmidiotis, Chief Scientific Officer, Avance Clinical (pictured on right with Jorgen Mould PhD, BSc (Hons) Avance Clinical’s Scientific Affairs Specialist – left).
This is in response to increased demand from biotechs for preclinical study management and scientific and regulatory advice to take their products to first-in-human trials.
The ClinicReady range of services constitutes a natural progression in Avance Clinical’s role as the premier provider of early drug development support to the biotechnology sector. The company recognises the major challenges faced by small biotechnology companies, particularly start-up companies who seek to drive their novel therapeutics to demonstration of safety and preliminary clinical Proof of Concept.
Drug Development Department
With ClinicReady, Avance Clinical’s team can act as a surrogate drug development department for start-up companies who are looking to benefit from a virtual model of operationalisation and execution from the early stages of drug candidate discovery to demonstration of preliminary clinical POC.